DCTH (Delcath Systems) Other Current Payables: $0.00 Mil (As of Mar. 2026)


DCTH Delcath Systems Inc DCTH
70 GF Score
Price $13.58
GF Value $37.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Delcath Systems Other Current Payables?

Delcath Systems DCTH +2.88% 70 Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $37.01 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Delcath Systems's Other Current Payables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Delcath Systems Other Current Payables Related Terms

Delcath Systems Other Current Payables Historical Data

* Premium members only.

The historical data trend for Delcath Systems's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delcath Systems Other Current Payables Chart

Delcath Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Delcath Systems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DCTH
70GF Score
Delcath Systems Inc DCTH
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delcath Systems Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Delcath Systems (DCTH) has a Other Current Payables of $0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Delcath Systems and its competitors.
Is Delcath Systems' Other Current Payables too high?
Delcath Systems' current Other Current Payables is $0.00 Mil. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Other Current Payables compare to VMD and VREX?
Delcath Systems' Other Current Payables of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Delcath Systems and its competitors. Delcath Systems's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $37.01, compared to a current price of $13.58 — trading 63.3% below its estimated fair value. The current Other Current Payables is $0.00 Mil. Delcath Systems' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $13.58 is trading 63.3% below its estimated GF Value™ of $37.01. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • Other Current Payables: $0.00 Mil
  • GF Value™: $37.01 vs. price of $13.58 (63.3% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score

Get the complete analysis for DCTH

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.58
Price
$37.01
GF Value